Trazidex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trazidex

What is Trazidex?

Trazidex is a fixed-dose combination ophthalmic medication designed for topical use in the eyes. It integrates two active pharmacological agents with distinct mechanisms of action to address specific ocular conditions involving both inflammation and the risk of bacterial infection.

Composition and Active Ingredients

The formulation consists of two primary components:

  • Tobramycin: A broad-spectrum aminoglycoside antibiotic. It works by inhibiting protein synthesis in susceptible bacteria, effectively addressing various Gram-negative and Gram-positive pathogens that commonly affect the external surface of the eye.
  • Dexamethasone: A potent synthetic corticosteroid. This component functions by suppressing the inflammatory response, reducing symptoms such as swelling, redness, and pain.

Therapeutic Purpose

Trazidex is primarily utilized in clinical settings where an inflammatory condition of the eye exists alongside a bacterial infection or a significant risk of developing one. By combining an anti-inflammatory agent with an antimicrobial, the medication allows for the simultaneous management of the underlying immune response and the infectious biological agent.

Common applications include the management of steroid-responsive inflammatory ocular conditions and the prevention of post-operative inflammation following ophthalmic surgeries, such as cataract procedures, where the prophylaxis of infection is a critical component of the recovery process.

Regulatory References

  1. Ophthalmic Steroid with Anti-infectives

What side effects are possible with Trazidex?

Possible Side Effects and Safety Information

Trazidex (a combination of the antibiotic tobramycin and the corticosteroid dexamethasone) may cause adverse reactions primarily affecting the eye, but systemic risks are also noted in regulatory documentation.

Common Adverse Reactions (Ocular)

These side effects are most frequently reported and are typically localized to the application area:

  • Eye or eyelid irritation, burning, or stinging
  • Eyelid itching or swelling
  • Eye redness (ocular hyperemia)
  • Ocular discomfort
  • Temporary blurred vision

Serious and Clinically Significant Risks

Safety data emphasizes that prolonged use, generally defined as 10 days or more, significantly increases the risk for serious ocular complications due to the corticosteroid component (dexamethasone):

  • Increased Intraocular Pressure (IOP): This can potentially lead to the development of glaucoma and associated damage to the optic nerve, resulting in vision loss.
  • Cataract Formation: Specifically, posterior subcapsular cataracts have been associated with extended use.
  • Secondary Infection: Prolonged use may result in the growth of non-susceptible organisms, including fungi, masking or enhancing the spread of new infections.
  • Ocular Perforation: The risk of creating a hole (perforation) in the globe is present when the drug is used in eyes with existing corneal or scleral thinning diseases.
  • Hypersensitivity Reactions: While uncommon, localized ocular toxicity (e.g., severe itching and swelling) and rare but serious systemic allergic reactions (e.g., anaphylaxis) have been reported.

Safety Considerations and Restrictions

  • Contraindications: The medicine is contraindicated in patients with most active viral diseases of the cornea and conjunctiva, notably Herpes Simplex Keratitis, as well as in mycobacterial and fungal infections of the eye, where the steroid component could worsen the condition.
  • Monitoring: Regular monitoring of intraocular pressure by an eye care professional is required, especially if the treatment course extends beyond 10 days.
  • Pediatric Use: Safety and effectiveness in children under 2 years of age have not been established through clinical trials.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Trazidex (Dexamethasone/Tobramycin ophthalmic formulation) addresses overdose scenarios resulting from excessive local application or accidental oral ingestion. Due to the minimal systemic absorption of the ingredients from the ocular surface, severe life-threatening systemic outcomes are generally not documented in regulatory labeling following local ocular overuse.

Documented Overdose Manifestations

Overdose from excessive topical administration presents primarily as localized ocular effects. The documented clinical signs and symptoms of local toxicity or hypersensitivity include eyelid edema, erythema (redness), lacrimation (tearing), eyelid itching, and the appearance of keratitis punctata (small lesions on the corneal surface).

Emergency Action and When to Seek Help

Regulatory guidance strictly mandates that immediate medical attention must be sought, and emergency services contacted, in the event of accidental oral ingestion of the product's contents. Management following acute systemic exposure is limited to symptomatic and supportive treatment as no specific antidote is known. For local overdose (excessive product in the eye), the officially described measure is to flush the eye(s) with tap water or sterile saline. Medical monitoring may be required following accidental ingestion.

Therapeutic Uses of Trazidex

What Trazidex Treats: Main Uses and Benefits

The medication is commonly used to provide supportive symptomatic relief across domains where a bacterial threat coincides with severe inflammation in the eye. It is generally applied in clinical settings marked by heightened patient distress resulting from these combined conditions. The combination is indicated for steroid-responsive inflammatory ocular conditions where a superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Indications that are often managed include inflammation of the palpebral and bulbar conjunctiva, inflammation of the cornea, chronic anterior uveitis, and corneal injury from burns or foreign bodies.

Relief and Clinical Context

This therapeutic domain addresses pronounced, disruptive manifestations like intense eye redness, swelling (edema), burning, and associated acute pain or irritation. Trazidex may be considered relevant when supportive symptom management is appropriate in situations involving superficial bacterial infection. It is often applied during the recovery phase post-surgery (like cataract removal) or post-injury (such as corneal trauma).

“This combined treatment supports general well-being during symptomatic phases and contributes to improved comfort during periods of heightened symptoms.”

The combination plays a role in managing symptoms and supporting the stability of the eye during these phases.

Quick Fact: Relief for Combined Symptoms
Primary Focus Conditions involving significant inflammation and bacterial risk.
Symptom Focus Redness, swelling, irritation, and pain associated with acute ocular conditions.
Clinical Context Post-surgery recovery and management of corneal injury.

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

The eligibility for Trazidex (Tobramycin/Dexamethasone Ophthalmic) is strictly defined by regulatory authorities and is determined by patient history and the type of ocular infection present.

Contraindications (Who Must Not Use)

This medication is absolutely contraindicated in patients with a known hypersensitivity to any component. It must not be used in the presence of specific infectious conditions due to the corticosteroid component, including:

  • Most viral diseases of the cornea and conjunctiva, such as epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella.
  • Fungal diseases of ocular structures.
  • Mycobacterial infection of the eye.

Age and Condition-Based Restrictions

Population/Condition Eligibility Status Key Restriction/Limitation
Pediatric Patients Established for ages ge 2 years Safety and effectiveness are not established in patients below the age of 2 years.
Pregnancy Restricted/Conditional Use only if the potential benefit justifies the potential risk to the fetus.
Prolonged Use Restricted/Conditional Intraocular Pressure (IOP) must be monitored if the product is used for 10 days or longer due to glaucoma risk.
Lactation/Nursing Conditional Caution should be exercised when administered to a nursing woman.

What should I know about interactions with other medicines?

Trazidex Interactions with other medicines and products


Interaction Scope

Trazidex is a combination of the antibiotic tobramycin and the corticosteroid dexamethasone applied topically to the eye. The interactions described below are based on the known behavior of these individual components.

Potential for Systemic Interactions (Low Risk)

Due to the topical administration, the amount of medicine absorbed into the rest of the body is generally very low, meaning the risk of systemic drug interactions is significantly reduced compared to taking these components as oral medications. However, the potential for certain interactions should still be considered.

  • CYP3A4 Inhibitors: The dexamethasone component may interact with medicines that strongly inhibit the CYP3A4 liver enzyme (e.g., ritonavir, cobicistat). This type of interaction can increase the level of corticosteroid in the body, potentially leading to side effects like Cushing's syndrome or adrenal suppression, especially if systemic absorption occurs.
  • Nephrotoxic or Ototoxic Agents: The tobramycin component belongs to a class of antibiotics that, when given systemically, can affect the kidneys and hearing. Concurrent use of this eye drop with other medicines known to cause kidney or inner ear toxicity should be noted, though the risk is minimal with ophthalmic use.

Procedural Constraints

If you are using other eye drops or ointments, wait at least 5 to 10 minutes between the applications of different products. Apply eye drops before eye ointments to ensure proper absorption.

Mechanism of Action

Trazidex is a fixed-dose combination containing tobramycin and dexamethasone, targeting bacterial growth and inflammatory cascades in localized tissues.

Tobramycin is an aminoglycoside that accumulates in bacterial cells. It interacts with the 30S ribosomal subunit, acting as an inhibitor of protein synthesis. This interaction causes a mistranslation of mRNA and the premature termination of polypeptide chains, resulting in the production of nonfunctional or toxic proteins. The intracellular consequence is a disruption of bacterial cellular integrity and function.

Dexamethasone is a synthetic glucocorticoid. It functions as an agonist of the cytosolic glucocorticoid receptor (GR). Upon ligand binding, the activated GR complex translocates into the cell nucleus, modifying gene transcription. This modification involves the induction of lipocortin (Annexin A1) synthesis, which acts as an intracellular inhibitor of phospholipase A2. This blocks the release of arachidonic acid, thereby suppressing the entire eicosanoid cascade, including the biosynthesis of prostaglandins and leukotrienes. Furthermore, dexamethasone represses the transcription of pro-inflammatory genes, including those encoding cyclooxygenase-2 (COX-2) and various cytokines, resulting in the systemic-level modulation of the localized inflammatory and immune response.

Dosage and Administration Information

How Trazidex is Used

Trazidex, a fixed-dose combination of dexamethasone and tobramycin, is strictly for topical ocular administration into the conjunctival sac(s). The medicine is supplied as an ophthalmic suspension and as an ophthalmic ointment. The ophthalmic suspension bottle must be shaken well prior to use to ensure the uniform distribution of the active components.


Standard Administration Schedule

Administration follows a dual-phase frequency schedule. Standard adult dosing involves applying one to two drops of the suspension or a one-half inch strip of the ointment into the affected eye(s).

Administration Phase Frequency Pattern
Acute/Initial Phase Up to one drop every two hours for the initial 24 to 48 hours, for severe conditions.
Standard Maintenance Typically every four to six hours (drops) or up to three to four times daily (ointment).

Procedural and Duration Guidelines

Treatment is intended for a short course, generally not to exceed a maximum of 24 days. The frequency must be decreased gradually as clinical signs improve, which constitutes a mandatory tapering protocol. To limit systemic absorption, a technique involving nasolacrimal occlusion (pressing the inner corner of the eye) for at least one minute after instillation is recommended. If another topical ophthalmic product is used concurrently, an interval of at least five minutes must be allowed between applications, with ointments always applied last.

Pediatric use is confined to children two years of age and older at the same dose as adults, as effectiveness and safety have not been established below this age threshold.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trazidex

The research that has explored the Tobramycin and Dexamethasone combination was studied for its use in short-term, acute conditions where both eye inflammation and a bacterial presence or risk of infection are involved. The evidence base largely consists of comparative clinical trials and regulatory data that reviewed the characteristics of the combination compared to other active treatments or established regimens.


Evidence for Conditions Involving Inflammation and Infection Risk

This section summarizes the foundational research—primarily short-term Randomized Controlled Trials (RCTs)—that regulators reviewed to assess the combination's use in steroid-responsive inflammatory ocular conditions where a superficial bacterial infection or risk of infection is present. These trials were typically applied in study populations of adult subjects presenting with symptoms associated with both ocular inflammation and an actual or potential bacterial issue.

The studies monitored outcomes related to clinical success, which involved composite evaluations of changes in specific ocular signs (like redness and swelling), and microbiological eradication, which tracked the clearance of pre-treatment bacterial pathogens. Reported outcomes were focused on the short time frame necessary to address the acute phase, and this body of evidence contributes to understanding symptom patterns over defined, brief time intervals.


Studies Following Ocular Surgery

This part of the research has explored the combination’s use in evaluating patient status following certain surgical procedures, such as uncomplicated cataract extraction. Research examined how the fixed-dose combination was evaluated when used as part of a post-operative care regimen, often in comparative RCTs against other established anti-inflammatory or anti-infective regimens. The study populations mainly involved middle-aged and older adults, and outcomes monitored included inflammatory signs in the anterior part of the eye, such as aqueous flare and cells, as well as patient-reported outcomes describing discomfort or pain.


Long-term Follow-up and Extended Observation Periods

The majority of the foundational research for the combination, particularly the regulatory studies, was designed to observe effects only for the short-term during the acute treatment phase (often 10 to 14 days, sometimes up to 4 weeks). As a result, there is limited information available from these controlled trials regarding long-term outcomes or the durability of observed symptom patterns beyond the defined study periods. Research that describes patient status over extended observation intervals is not fully established in the evidence base.

Key Studies & References

  1. NIH DailyMed: Tobramycin and Dexamethasone Ophthalmic Suspension (Official Labeling and Indications)
  2. NIH National Library of Medicine (NLM) Drug Classification and Structured Product Labeling Information

Frequently Asked Questions (FAQ)

Common questions about Trazidex (FAQ)


Q: How quickly does Trazidex typically start to show its effects?

Regulatory documents indicate that the most frequent and intensive administration schedule is reserved for the initial 24 to 48 hours in severe cases. This scheduling indicates that the medication's effects are typically addressed or observed early in the course of acute treatment.


Q: Is Trazidex considered a long-term or short-term treatment?

Trazidex is intended for a short course of treatment, generally not exceeding a maximum of 24 days. Regulatory warnings indicate that prolonged use is associated with an increased risk of complications, such as elevated intraocular pressure and cataract formation.


Q: Are there any specific foods or drinks that should be avoided when taking Trazidex?

Due to its topical application, the medicine is not typically associated with specific food or drink restrictions. However, because one component of Trazidex (dexamethasone) can interact with strong enzyme inhibitors, for any concerns regarding potential interactions, official guidance suggests consultation with a healthcare professional.


Q: Can Trazidex be taken alongside common over-the-counter pain relievers?

Since the medicine is applied topically to the eye, the amount absorbed into the rest of the body is generally very low. Because of this low systemic absorption, the risk of systemic drug interactions with common pain relievers is generally low.


Q: Is there a known interaction between Trazidex and alcohol?

Official documents do not typically specify a direct interaction between this topical medicine and alcohol due to the expected low systemic absorption into the bloodstream.


Q: What information is available about Trazidex use during pregnancy?

Regulatory information indicates that adequate and well-controlled studies evaluating the effects of Trazidex in pregnant women have not been conducted. Regulatory guidance suggests that use in pregnancy is reserved for situations where the potential benefit is considered to justify the potential risk.


Q: What is known about Trazidex use while breastfeeding?

Official information states that caution should be exercised regarding use when administered to a nursing patient. This caution is based on the fact that some drugs in the same class may be excreted in human milk.


Q: Does Trazidex require any special monitoring or regular blood tests?

Yes, regular monitoring of intraocular pressure (IOP) by an eye care professional is required, particularly if the duration of use is 10 days or longer. This monitoring is a precaution related to the corticosteroid component. Regulatory documents do not require routine blood tests.


Q: If I have a kidney condition, can I still take Trazidex?

Since the medicine is administered topically and has low systemic absorption, official documents do not list pre-existing kidney conditions as a specific contraindication for the ophthalmic formulation. The component that can affect the kidneys (tobramycin) is mainly associated with systemic (oral or injected) use.


Q: Does Trazidex interact with blood pressure medications?

Systemic interactions with common drug classes like blood pressure medications are not typically expected due to the low absorption of the medicine into the bloodstream after topical application. Official documents primarily focus on interactions with strong enzyme inhibitors.


Q: Can Trazidex be split or crushed if someone has trouble swallowing pills?

Trazidex is an ophthalmic suspension (liquid drops) or ointment and is not a tablet or capsule intended for swallowing. It is designed to be applied topically to the eye.


Q: What is the official chemical or generic name for Trazidex?

Trazidex is a brand name. The drug is a fixed-dose combination product containing two active ingredients: the antibiotic tobramycin and the corticosteroid dexamethasone.


Q: Why do official documents mention that Trazidex should be used with caution in certain groups?

Official documents recommend caution primarily because of the potential for serious ocular risks associated with the corticosteroid component (dexamethasone). These risks include increased intraocular pressure (potential for glaucoma) and cataract formation, especially when the drug is used for longer than recommended.


Q: Can Trazidex affect my ability to drive or operate machinery?

Temporary visual blurring is a possible adverse reaction following application. Official cautions indicate that patients experiencing visual blurring should wait until vision is clear before driving or operating machinery.


Q: Do all people who take Trazidex experience side effects?

No. Official data indicates that the most frequently reported adverse reaction, ocular discomfort, occurred in approximately 10% of patients in clinical studies. All other adverse reactions occurred with a frequency of less than 1%.


Q: Is Trazidex known to interact with herbal supplements?

Official information notes that herbal remedies and supplements are not tested in the same rigorous manner as prescription medicines. Therefore, there is limited official information available regarding potential interactions between Trazidex and these products.


Q: How does Trazidex fit into the class of medicine it belongs to?

Trazidex is formally classified as an Ophthalmic Corticosteroid and Anti-infective Combination. It combines an anti-inflammatory agent (dexamethasone) with an antibiotic (tobramycin) for topical use in the eye.


Q: Are there different versions or brands of Trazidex available?

Trazidex is a brand name for the combination of tobramycin and dexamethasone. Other ophthalmic products containing the same active ingredients may be available, including generic versions of the combination, subject to local regulatory status.


Q: What is the risk of overdose with Trazidex?

The potential for acute overdose is generally low due to the topical administration of the medicine. If excessive amounts are accidentally applied, the symptoms would be expected to be an exaggeration of the known side effects, which are generally localized to the eye.


Q: Is Trazidex a controlled substance in my country?

Trazidex is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA) or similar regulatory systems. It is regulated as a prescription-only medicine.


Q: Is Trazidex affected by grapefruit juice, like some other medicines?

While one component of Trazidex can interact with strong enzyme inhibitors when absorbed systemically, there are typically no specific regulatory warnings about grapefruit juice for the topical ophthalmic form due to its low absorption into the bloodstream.


Q: Is there a specific time of day Trazidex is usually recommended to be taken?

The official administration instructions are based on a required frequency (e.g., up to every two hours initially, then every four to six hours). Regulatory documents do not specify a fixed time of day (such as morning or night) for administration, focusing instead on the required interval between doses.


Q: What kinds of medical conditions may make Trazidex unsuitable for a person?

The medicine is specifically contraindicated (unsuitable) for patients with most active viral diseases of the eye, such as Herpes Simplex Keratitis, as well as for fungal or mycobacterial infections of the eye, as the steroid component could potentially worsen these conditions.


Q: Does Trazidex commonly cause stomach upset?

No. The most commonly reported adverse reactions are localized to the eye, such as eye irritation, ocular discomfort, and temporary blurred vision. Stomach upset is not listed among the common adverse reactions for the ophthalmic formulation.


Q: Are there any warnings about suddenly stopping Trazidex treatment?

Official administration instructions specify that the frequency of use should be decreased gradually as clinical signs improve. This constitutes a mandatory tapering protocol, as the sudden cessation of a corticosteroid treatment can sometimes lead to a rebound or flare-up of the condition.


Q: Is Trazidex a type of hormone treatment?

One of the active ingredients in Trazidex, dexamethasone, is defined as a synthetic glucocorticoid. Glucocorticoids are a type of steroid hormone that works by modifying the body's inflammatory and immune response.


Q: Can Trazidex cause headaches or dizziness?

Yes, regulatory data indicates that headaches and dizziness have been identified as possible adverse reactions reported in the post-marketing experience with this type of ophthalmic product. These are not typically the most common side effects.

How should Trazidex be stored and disposed of?

The official regulatory instructions for Trazidex (Tobramycin and Dexamethasone Ophthalmic Suspension) specify strict storage and disposal requirements to ensure product integrity.

Storage Conditions

Requirement Details
Temperature Store at a controlled temperature range of 2 C to 25 C (36 F to 77 F). Do not freeze.
Protection Keep the bottle tightly closed in the original container and protect from light.
Handling The suspension must be shaken well before each use.
Child Safety Keep out of the sight and reach of children.

Stability and Disposal

The in-use stability period for the ophthalmic suspension requires the product to be discarded 28 days (4 weeks) after the first opening. Regarding disposal, the medicine must not be thrown away via wastewater or household trash. Unused or expired Trazidex should be disposed of through an authorized drug take-back program or as directed by local regulatory authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trazidex found in:

A-Z Index: